442 related articles for article (PubMed ID: 26485309)
41. Long-term memory deficits in Huntington's disease are associated with reduced CBP histone acetylase activity.
Giralt A; Puigdellívol M; Carretón O; Paoletti P; Valero J; Parra-Damas A; Saura CA; Alberch J; Ginés S
Hum Mol Genet; 2012 Mar; 21(6):1203-16. PubMed ID: 22116937
[TBL] [Abstract][Full Text] [Related]
42. Partial depletion of CREB-binding protein reduces life expectancy in a mouse model of Huntington disease.
Klevytska AM; Tebbenkamp AT; Savonenko AV; Borchelt DR
J Neuropathol Exp Neurol; 2010 Apr; 69(4):396-404. PubMed ID: 20448484
[TBL] [Abstract][Full Text] [Related]
43. RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model.
Harper SQ; Staber PD; He X; Eliason SL; Martins IH; Mao Q; Yang L; Kotin RM; Paulson HL; Davidson BL
Proc Natl Acad Sci U S A; 2005 Apr; 102(16):5820-5. PubMed ID: 15811941
[TBL] [Abstract][Full Text] [Related]
44. Specific promoter deacetylation of histone H3 is conserved across mouse models of Huntington's disease in the absence of bulk changes.
Guiretti D; Sempere A; Lopez-Atalaya JP; Ferrer-Montiel A; Barco A; Valor LM
Neurobiol Dis; 2016 May; 89():190-201. PubMed ID: 26851501
[TBL] [Abstract][Full Text] [Related]
45. Transcriptional dysregulation of coding and non-coding genes in cellular models of Huntington's disease.
Bithell A; Johnson R; Buckley NJ
Biochem Soc Trans; 2009 Dec; 37(Pt 6):1270-5. PubMed ID: 19909260
[TBL] [Abstract][Full Text] [Related]
46. AAV-mediated delivery of the transcription factor XBP1s into the striatum reduces mutant Huntingtin aggregation in a mouse model of Huntington's disease.
Zuleta A; Vidal RL; Armentano D; Parsons G; Hetz C
Biochem Biophys Res Commun; 2012 Apr; 420(3):558-63. PubMed ID: 22445760
[TBL] [Abstract][Full Text] [Related]
47. Clinico-pathological rescue of a model mouse of Huntington's disease by siRNA.
Wang YL; Liu W; Wada E; Murata M; Wada K; Kanazawa I
Neurosci Res; 2005 Nov; 53(3):241-9. PubMed ID: 16095740
[TBL] [Abstract][Full Text] [Related]
48. Sustained effects of nonallele-specific Huntingtin silencing.
Drouet V; Perrin V; Hassig R; Dufour N; Auregan G; Alves S; Bonvento G; Brouillet E; Luthi-Carter R; Hantraye P; Déglon N
Ann Neurol; 2009 Mar; 65(3):276-85. PubMed ID: 19334076
[TBL] [Abstract][Full Text] [Related]
49. Impaired Replenishment of Cortico-Striatal Synaptic Glutamate in Huntington's Disease Mouse Model.
Buren C; Tu G; Raymond LA
J Huntingtons Dis; 2020; 9(2):149-161. PubMed ID: 32310183
[TBL] [Abstract][Full Text] [Related]
50. Selective degeneration in YAC mouse models of Huntington disease.
Van Raamsdonk JM; Warby SC; Hayden MR
Brain Res Bull; 2007 Apr; 72(2-3):124-31. PubMed ID: 17352936
[TBL] [Abstract][Full Text] [Related]
51. Transcriptional correlates of the pathological phenotype in a Huntington's disease mouse model.
Gallardo-Orihuela A; Hervás-Corpión I; Hierro-Bujalance C; Sanchez-Sotano D; Jiménez-Gómez G; Mora-López F; Campos-Caro A; Garcia-Alloza M; Valor LM
Sci Rep; 2019 Dec; 9(1):18696. PubMed ID: 31822756
[TBL] [Abstract][Full Text] [Related]
52. Mechanisms of disease: Histone modifications in Huntington's disease.
Sadri-Vakili G; Cha JH
Nat Clin Pract Neurol; 2006 Jun; 2(6):330-8. PubMed ID: 16932577
[TBL] [Abstract][Full Text] [Related]
53. Brain urea increase is an early Huntington's disease pathogenic event observed in a prodromal transgenic sheep model and HD cases.
Handley RR; Reid SJ; Brauning R; Maclean P; Mears ER; Fourie I; Patassini S; Cooper GJS; Rudiger SR; McLaughlan CJ; Verma PJ; Gusella JF; MacDonald ME; Waldvogel HJ; Bawden CS; Faull RLM; Snell RG
Proc Natl Acad Sci U S A; 2017 Dec; 114(52):E11293-E11302. PubMed ID: 29229845
[TBL] [Abstract][Full Text] [Related]
54. Histone deacetylase knockouts modify transcription, CAG instability and nuclear pathology in Huntington disease mice.
Kovalenko M; Erdin S; Andrew MA; St Claire J; Shaughnessey M; Hubert L; Neto JL; Stortchevoi A; Fass DM; Mouro Pinto R; Haggarty SJ; Wilson JH; Talkowski ME; Wheeler VC
Elife; 2020 Sep; 9():. PubMed ID: 32990597
[TBL] [Abstract][Full Text] [Related]
55. Phosphorylation of huntingtin at Ser421 in YAC128 neurons is associated with protection of YAC128 neurons from NMDA-mediated excitotoxicity and is modulated by PP1 and PP2A.
Metzler M; Gan L; Mazarei G; Graham RK; Liu L; Bissada N; Lu G; Leavitt BR; Hayden MR
J Neurosci; 2010 Oct; 30(43):14318-29. PubMed ID: 20980587
[TBL] [Abstract][Full Text] [Related]
56. In vivo proof-of-concept of removal of the huntingtin caspase cleavage motif-encoding exon 12 approach in the YAC128 mouse model of Huntington's disease.
Casaca-Carreira J; Toonen LJA; Evers MM; Jahanshahi A; van-Roon-Mom WMC; Temel Y
Biomed Pharmacother; 2016 Dec; 84():93-96. PubMed ID: 27639545
[TBL] [Abstract][Full Text] [Related]
57. Differential effects of voluntary physical exercise on behavioral and brain-derived neurotrophic factor expression deficits in Huntington's disease transgenic mice.
Pang TYC; Stam NC; Nithianantharajah J; Howard ML; Hannan AJ
Neuroscience; 2006 Aug; 141(2):569-584. PubMed ID: 16716524
[TBL] [Abstract][Full Text] [Related]
58. Epigenetic modifications as novel therapeutic targets for Huntington's disease.
Wang F; Fischhaber PL; Guo C; Tang TS
Epigenomics; 2014 Jun; 6(3):287-97. PubMed ID: 25111483
[TBL] [Abstract][Full Text] [Related]
59. Neonatal iron supplementation potentiates oxidative stress, energetic dysfunction and neurodegeneration in the R6/2 mouse model of Huntington's disease.
Berggren KL; Chen J; Fox J; Miller J; Dodds L; Dugas B; Vargas L; Lothian A; McAllum E; Volitakis I; Roberts B; Bush AI; Fox JH
Redox Biol; 2015; 4():363-74. PubMed ID: 25703232
[TBL] [Abstract][Full Text] [Related]
60. Effects of deletion of mutant huntingtin in steroidogenic factor 1 neurons on the psychiatric and metabolic phenotype in the BACHD mouse model of Huntington disease.
Baldo B; Cheong RY; Petersén Å
PLoS One; 2014; 9(10):e107691. PubMed ID: 25271967
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
